These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2412021)

  • 41. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single administration of captopril and combined use with beta-blocker and/or thiazide diuretic in the treatment of essential hypertension.
    Yoneda S; Kako T; Koketsu M; Hayano J; Asakawa T; Fujinami T; Kato T
    Angiology; 1991 Nov; 42(11):914-23. PubMed ID: 1683186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Angiotensin receptor blockers for management of hypertension.
    Catanzaro DF; Frishman WH
    South Med J; 2010 Jul; 103(7):669-73. PubMed ID: 20531060
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A new principle in long-term treatment of essential hypertension: angiotensin-converting enzyme inhibition (author's transl)].
    Overlack A; Stumpe KO; Heck I; Krück F
    Dtsch Med Wochenschr; 1980 Apr; 105(15):505-9. PubMed ID: 6244920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].
    Andréjak M; Slama M; Hary L
    Therapie; 1998; 53(3):291-300. PubMed ID: 9773129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of drug-resistant hypertension with minoxidil or angiotensin-converting enzyme inhibitor: blood pressure, renin, aldosterone, and electrolyte responses.
    Baer L; Radichevich I; Williams GS
    J Cardiovasc Pharmacol; 1980; 2 Suppl 2():S206-16. PubMed ID: 6156357
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects.
    MacGregor GA; Markandu ND; Bayliss J; Roulston JE; Squires M; Morton JJ
    Br Med J (Clin Res Ed); 1981 Aug; 283(6288):401-3. PubMed ID: 6266576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
    Azizi M; Guyene TT; Chatellier G; Ménard J
    J Hypertens; 1994 Apr; 12(4):419-27. PubMed ID: 8064166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [New therapeutic approaches to arterial hypertension].
    Waeber B; Brunner HR
    Schweiz Med Wochenschr; 1982 Sep; 112(39):1330-4. PubMed ID: 6755692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prolonged converting enzyme inhibition in non-modulating hypertension.
    Dluhy RG; Smith K; Taylor T; Hollenberg NK; Williams GH
    Hypertension; 1989 Apr; 13(4):371-7. PubMed ID: 2538393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal artery stenosis with normal angiotensin II values. Relationship between angiotensin II and body sodium and potassium on correction of hypertension by captopril and subsequent surgery.
    Atkinson AB; Brown JJ; Davies DL; Leckie B; Lever AF; Morton JJ; Robertson JI
    Hypertension; 1981; 3(1):53-8. PubMed ID: 7009427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
    Lazich I; Bakris GL
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):471-5. PubMed ID: 21709549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rate of activation of renin-angiotensin-aldosterone axis and sodium intake in rats.
    Holtzman E; Braley LM; Menachery A; Williams GH; Hollenberg NK
    Am J Physiol; 1989 May; 256(5 Pt 2):H1311-5. PubMed ID: 2655479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of converting enzyme inhibition on blood pressure, plasma renin activity (PRA) and plasma aldosterone in hypertensive diabetics compared to patients with essential hypertension.
    Sullivan PA; Kelleher M; Twomey M; Dineen M
    J Hypertens; 1985 Aug; 3(4):359-63. PubMed ID: 2995484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension.
    Iimura O; Shimamoto K
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S63-6. PubMed ID: 2474107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug treatment of essential hypertension: the case for initial combination therapy.
    Welsh L; Ferro A
    Int J Clin Pract; 2004 Oct; 58(10):956-63. PubMed ID: 15587775
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trends in antihypertensive treatment--lessons from the National Acute Stroke Israeli (NASIS) registry.
    Koifman E; Tanne D; Molshatzki N; Leibowitz A; Grossman E
    Blood Press; 2014 Oct; 23(5):262-9. PubMed ID: 24483945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Converting enzyme inhibitors normalize the reduced adrenal responsiveness to angiotensin II in essential hypertension.
    Williams GH; Hollenberg NK
    J Hypertens Suppl; 1984 Dec; 2(2):S43-7. PubMed ID: 6100876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitors of the renin-angiotensin system. Effects on blood pressure, aldosterone secretion and renal function.
    Atlas SA; Niarchos AP; Case DB
    Am J Nephrol; 1983; 3(2-3):118-27. PubMed ID: 6191567
    [No Abstract]   [Full Text] [Related]  

  • 60. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.
    Sim JJ; Bhandari SK; Shi J; Kalantar-Zadeh K; Rasgon SA; Sealey JE; Laragh JH
    Am J Hypertens; 2012 Mar; 25(3):379-88. PubMed ID: 22158065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.